Marc Penn, M.D., Ph.D.
| Appointed: |
2000 |
| Gender: |
Male |
| Languages: |
English |
Cardiovascular Medicine
Critical Care Center
Stem Cell Biology and Regenerative Medicine
Biomedical Engineering
Bakken Heart-Brain Institute
Biographical Sketch
Dr. Marc Penn is Medical Director of the Cardiac Intensive Care Unit at the Cleveland Clinic, a staff cardiologist in the Section of Clinical Cardiology, Department of Cardiovascular Medicine, at Cleveland Clinic Heart and Vascular Institute, and in the Department of Cell Biology. He is also the Director of the Experimental Animal Laboratory and Associate Director of the Cardiovascular Medicine Fellowship Training Program. Dr. Penn is board certified in Internal Medicine and Cardiovascular Medicine. He has a special interest in myocardial ischemia, vascular biology, cardiac critical care and stem cell and gene therapy for the regeneration of myocardial function.
Dr. Penn completed his undergraduate and post graduate work at Case Western Reserve University earning honors on his way to completing a Ph.D. in Biomedical Engineering. Dr. Penn earned his medical degree from Case Western Reserve University School of Medicine. He completed his clinical training at University Hospitals of Cleveland before being offered a Fellowship to the Cleveland Clinic Foundation Department of Cardiology. He joined the Cleveland Clinic in 2000.
Dr. Penn's education and training have helped him develop drug delivery systems for the treatment of cardiovascular disease, including studies to optimize gene therapy and stem cell therapy for the regeneration of myocardial tissue. Dr. Penn has an academic appointment at Case Western Reserve University in the Department of Biomedical Engineering. He is recipient of the 2000 Joseph Cash Memorial Prize for Clinical Outcomes Research and the 1999 Irvine H. Page Young Investigator award presented by the American Heart Association, among others. He is the recipient of a number of research grants and has been the principal site investigator in the clinical trials for the International Registry of Aortic Dissections.
In 2001, Dr. Penn was named director of the Experimental Animal Laboratory in the Department of Cardiovascular Medicine at the Cleveland Clinic. This laboratory is dedicated to the discovery and implementation of novel drug and gene therapies, as well as devices for the treatment of cardiovascular disease in clinical populations.
He serves as a reviewer for a number of journals including the American Journal of Physiology, Cardiovascular Research, Diabetes Care, the Journal of Leukocyte Biology, Circulation, and The Lancet. Dr. Penn has been an invited lecturer at symposiums and conferences and is author or co-author of many published articles, abstracts and book chapters on a wide range of topics, including the effects of lipoprotein oxidation and lipoprotein-induced cell injury in diabetes; mechanism of clot formation in atherosclerotic arteries, optimal management of patients with acute aortic dissection, and cell and gene based therapies for heart failure.
Dr. Penn belongs to the American Society of Gene Therapy, and the Arteriosclerosis, Thrombosis and Vascular Biology and the Basic Cardiovascular Sciences Councils of the American Heart Association. He is currently President for the American Heart Association, Cleveland Metro Division.
Education & Fellowships
| Medical School: | Case Western Reserve University School of Medicine, Cleveland, OH |
|
| Residency: | University Hospitals of Cleveland, Medicine, Cleveland, OH |
| Fellowship: | Cleveland Clinic, Cardiology, Cleveland, OH |
| Other Education: | (Undergraduate) Case Western Reserve University, Cleveland, OH |
Certifications
Specialty Interests
Myocardial ischemia, vascular biology, cardiac critical care.
Specializes in Diseases and Conditions
Specializes in Services
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 10/17/2008, Dr. Penn has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
Consulting. Dr. Penn receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
- Cardax Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Schering-Plough Corporation
Royalty Payments. Dr. Penn has the right to receive royalty payments for inventions or discoveries related to the companies shown below:
- Abbott Laboratories, Inc.
- BioHeart Inc.
- Biosite Incorporated
- Siemens
Equity. Dr. Penn owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
- AcelleRX Therapeutics, Inc.
- Cardionomic, Inc.
- Cour Pharmaceuticals
- PrognostiX, Inc.
- VitalStream Health, Inc.
Inventor Share. Dr. Penn may receive future financial benefits from the Cleveland Clinic for inventions or discoveries related to the companies shown below:
- AcelleRX Therapeutics, Inc.
- Autonomic Technologies
- Cardionomic, Inc.
- IntElect Medical Inc.
- PrognostiX, Inc.
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
